the aid library

World Health Organization WHO (2021) C_WHO

10 May 2021. Manufactureres: SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)] The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto ... more

Download

View PDF

Health in the Americas 2022: Overview of the Region of the Americas in the context of the COVID-19 pandemic

Pan American Health Organisation PAHO (2022) C_WHO

The objective of Health in the Americas: Overview of the Region of the Americas in the Context of the COVID-19 Pandemic is to respond to the need to address important public health issues in an increasingly timely manner, while serving as a platform with a close focus on specific issues of regional ... more

Download

View PDF

Medicinal products under development for the treatment of Ebola

European Medicines Agency EMA (2014)

Interim Assessement Report The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte ... more

Download

View PDF

Field Guide for Preparedness and Response to Diphtheria Outbreaks in the Western Pacific Region

World Health Organization WHO (2023) C_WHO

Due to high routine vaccination coverage, overall counts of diphtheria case have significantly declined in the Western Pacific Region recently. However, diphtheria is still prevalent in several countries and areas of the Region and remains a public health issue due to its high case fatality rate. ... more

External Link

World Heart Federation Cholesterol Roadmap 2022

Ray, K.K.; Ference, B.A.; Séverin, T. et al. World Heart Federation (2022) CC

Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial infarction, stroke and peripheral arterial disease continue to be major causes of premature death, disability and healthcare expenditure globally. Preventing the accumulation of cholesterol-containing atherogenic lipopr ... more

Download

View PDF

Лекарственная терапия при COVID-19

World Health Organization WHO (2021) C_WHO

Вариативные рекомендации 24 сентября 2021 г. Этот документ представляет собой текущие рекомендации ВОЗ. В них будут вноситься изменения и дополнения, касающиеся нов ... more

Download

View PDF

Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021
recommended

World Health Organization WHO (2021) CC

This document aims to describe a minimum set of surveillance activities recommended at the national level to detect and monitor the relative prevalence of SARS-CoV-2 variants and outline a set of activities for the characterization and assessment of risk posed by these variants. A set of indicators ... more

Download

View PDF

COVID Reference 2021.6 EN
recommended

Kamps, B.S.; Camp, R. and C. Hoffmann (2021) CC

Download

View PDF

COVID-19 Scientific and Public Health Policy Update – (6 July 2022)

African Union; Africa CDC Centres for Disease Control and Prevention (2022) C1

This bi-weekly brief details the latest developments in scientific knowledge and public health policy from around the world as well as updates to the COVID-19-related guidance from Africa CDC, WHO and other public health agencies.

Download

View PDF

Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration

E. J. Abrams; J. Ananworanich; M. Archary; M.N. Ngongondo; P. Brouwers J Acquir Immune Defic Syndr; Pub Med (2018) C2

J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018

Download

View PDF

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download

View PDF

The ACT-Accelerator: Two years of impact

World Health Organization WHO (2022) C_WHO

The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.

External Link

Management of severe paediatric malaria in resource-limited settings

Maitland, K. (2015) CC2

BMC Medicine (2015) 13:42 DOI 10.1186/s12916-014-0263-6

Download

View PDF

Global Disease Detection (GDD) Manual “Rapid Diagnostic Tests for Epidemic Diseases”

Center for Disease Control Centers for Disease Control and Prevention (CDC) (2011) C_CDC

Download

View PDF

Zika Virus Research Agenda - October 2016

World Health Organization WHO (2016) C_WHO

Download

View PDF

Responding to a poliovirus event or outbreak - Part 2: Protocol for poliovirus type 2

Global Polio Eradication Initiative WHO (2017) C_WHO

The main objectives of the SOPs are to: (i) establish standards and timelines for response activities; and (ii) guide national governments and GPEI partners in key support functions. This new version of the SOPs presents overall response requirements for dealing with type 1, 2 and 3 poliovirus fo ... more

Download

View PDF

Diphtheria vaccine: WHO position paper – August 2017. Vaccin antidiphtérique: Note de synthèse de l’OMS – août 2017

World Health Organization WHO (2017) C_WHO

Weekly epidemiological record/ Relevé épidémiologique hebdomadaire 4 AUGUST 2017, 92th YEAR / 4 AOÛT 2017, 417-436

Download

View PDF

2021 Antibacterial agents in clinical and preclinical development: an overview and analysis

World Health Organization WHO (2022) C_WHO

This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development. The analysis covers traditional (direct-acting small molecules) and non-traditional antibacterial agents in development worldwide. It evaluates to what extent ... more

Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021 recommended

COVID Reference 2021.6 EN recommended

Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021
recommended

COVID Reference 2021.6 EN
recommended